NEW ZEALAND DATA SHEET - Medsafe

Madopar (levodopa) Data Sheet (DS) - Medsafe

MADOPAR 160202 1 Data Sheet MADOPAR® Levodopa + benserazide Capsules 62.5, 125 and 250; dispersible tablet 62.5; HBS modified-release capsule 125

  Levodopa, Dispersible

Section 1: Legislation - Medsafe Home Page

Section 2: Overview of Regulation of Clinical Trials in New Zealand . Section summary Under Section 30 of the Medicines Act 1981, approval from the Director-General of

  Section, Clinical, Legislation, Section 1

Section 1: Legislation relating to the labelling - …

Part 5, Ed 1.6 Page 2 of 18 . Section 1: Legislation relating to the labelling of medicines and related products Section summary This section lists the legislation regulating the labelling of medicines and related products.

  Section, Relating, Legislation, Labelling, Section 1, Legislation relating to the labelling

NEW ZEALAND DATA SHEET VERMOX® - …

NEW ZEALAND DATA SHEET VERMOX® Vermox® Page 2 of 7 For control of enterobiasis Adults and children 2-12 years: 1 Vermox tablet (100 mg) or 5 mL of suspension (100 mg) is given.

Guideline on the Regulation of Therapeutic …

Guideline on the Regulation of Therapeutic Products in New Zealand Part 10: Requirements for information for prescribers and consumers Edition 7.0

  Guidelines, Product, Regulations, Therapeutic, Guideline on the regulation of therapeutic, Guideline on the regulation of therapeutic products in

Clonazepam: oral drops (2.5 mg/ml); injection (1 mg).

2. you have severe and chronic lung disease 3. you have severe liver disease 4. you have an addiction to drugs or alcohol 5. the package is torn or shows signs of tampering

  Clonazepam

NEW ZEALAND DATA SHEET - Medsafe

NEW ZEALAND DATA SHEET 5 Hypnovel 170717 Medical history of alcohol or drug abuse Hypnovel should be avoided in patients with a medical history of alcohol or drug abuse.

  Drug

SCHEDULE OF FEES (effective from 1 July 2018)

Page 1 of 10. SCHEDULE OF FEES (effective from 1 July 2018) • All fees listed are GST inclusive. • More detailed descriptions of the type of application or change to which a fee applies can be

  Schedule, Effective, Fees, Schedule of fees

Nortriptyline (as hydrochloride) 10 mg and 25 mg Tablets

1 Nortriptyline NRIM 09052013 NEW ZEALAND DATA SHEET Nortriptyline NRIM . Nortriptyline (as hydrochloride) 10 mg and 25 mg Tablets . This product may not be interchangeable with similar products on the New Zealand market

2. QUALITATIVE AND QUANTITATIVE COMPOSITION 3 ...

1. PRODUCT NAME LOSARTAN ACTAVIS (Losartan Potassium 12.5mg, 25mg, 50mg and 100mg Tablets) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains: 12.5 mg losartan potassium 25 mg losartan potassium 50 mg losartan potassium 100mg losartan potassium . For the full list of excipients, see section 6.1. 3. …

  Product, Name, Qualitative, Losartan, Product name losartan

Page 1 of 4 BEVACIZUMAB Bevacizumab in combination with ...

Prior anthracycline exposure and/or prior radiation to the chest wall may be possible risk factors for the development of CHF. Caution should be exercised before initiating Bevacizumab therapy in patients with these risk factors.

  With, Combination, Bevacizumab, Bevacizumab bevacizumab in combination with

DRUG NAME: Bevacizumab - BC Cancer

Bevacizumab SPECIAL PRECAUTIONS: Contraindicated in patients who have: • a history of hypersensitivity reaction to bevacizumab or other recombinant human …

  Name, Drug, Drug name, Bevacizumab

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Bevacizumab in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.

  Bevacizumab

PROTEIN-PROTEIN INTERACTIONS, VISCOSITY AND …

protein-protein interactions, viscosity and injectability in multi protein co-formulations-bevacizumab and ralbumin second generation albumin fusions

  Interactions, Viscosity, Protein, Bevacizumab, Protein interactions, Viscosity and, Viscosity and injectability in, Injectability

T2047 An ELISA for the Quantitative Determination of Free ...

An ELISA for the Quantitative Determination of Free and Partially Bound Bevacizumab in Human Serum . T2047 . John Kamerud*, Mark Abrams and Jon Klover.

  Free, Determination, Quantitative, Aisle, Bevacizumab, Elisa for the quantitative determination, Elisa for the quantitative determination of free and

Our Clinical Trials - Amgen Oncology

Amgen aspires to be the best human therapeutics company. Amgen is committed to developing new therapies to treat serious illnesses — a long and careful process.

  Clinical, Trail, Our clinical trials